Brief: Enlivex Receives Notice Of Allowance For U.S. Patent Application Covering Treatment Of Sepsis Patients With Allocetra
06/12/2021 15:09
Dec 6 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX RECEIVES NOTICE OF ALLOWANCE FOR U.S. PATENT
APPLICATION
COVERING TREATMENT OF SEPSIS PATIENTS WITH ALLOCETRA
* ENLIVEX THERAPEUTICS LTD - EXPECTS THAT THIS NEW PATENT
WILL BE
ISSUED IN THE UNITED STATES IN EARLY 2022
* ENLIVEX THERAPEUTICS - PATENT WILL PROVIDE ADDED IP
PROTECTION
IN U.S. AT LEAST THROUGH 2036 WITH CLAIMS COVERING USE OF
ALLOCETRA
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment